Governor Abigail Spanberger announced plans to veto major healthcare affordability proposal about Prescription Drug prices passed by the Virginia General Assembly

By Eric Silber

​The bill, introduced as Senate Bill 271 and House Bill 483, would have created a Prescription Drug Affordability Board (PDAB) within Virginia's State Department of Health. The proposed board would have reviewed certain high-cost prescription medications, and, under specific conditions, would have been authorized to establish upper payment limits tied to federally negotiated drug prices.

The legislation was sponsored in the Senate by Senator Creigh Deeds (D) and in the House by Delegate Carrie Delaney (D). It received bipartisan support in both chambers of the General Assembly.

Supporters of the bill argue that it represented a direct effort to address rising prescription drug costs for Virginians. Organizations including the AARP publicly supported the proposal, citing concerns about affordability for seniors and families facing increasing medication expenses.

​Opposition to the legislation came from several pharmaceutical industry groups and healthcare policy organizations (Big Pharma). Critics argue that the board's authority to establish upper payment limits could create unintended consequences involving prescription drug access, insurance markets, or pharmaceutical innovation. Lobbying groups tied to these critics have spent significant amounts of money against this bill.
     

Before issuing the veto, Governor Spanberger proposed amendments that would have substantially changed the structure of the board. Her amendments would have limited the board's authority and delayed implementation of binding pricing actions pending additional legislative approval. The General Assembly declined to adopt these amendments.

Because of the disagreements between the governor and the General Assembly, Spanberger vetoed the bill. In statements surrounding the veto decision the Governor's office indicated that while the administration supports efforts to reduce healthcare costs, concerns remained about whether the legislation would guarantee direct savings for patients and whether additional policy refinement was needed before implementation. 

​The veto has prompted discussion among Democrats and healthcare advocates across Virginia. Some lawmakers and advocacy groups expressed disappointment, noting that prescription drug affordability was a major issue during recent statewide campaigns. Others have argued that the governor's concerns regarding implementation oversight deserve further consideration. At this stage, the legislation will not take effect unless lawmakers pursue further action in a future legislative session.